Biblio Discovery — Demo Discovery Service

12 results for "Viive M. Howell"

Showing 1–12 · 1.41 seconds · RSS

  1. Journal Article

    Why the dual origins of high grade serous ovarian cancer matter

    Emily K. Colvin; Viive M. Howell

    Nature Communications, Vol. 11 No. 1 · 2020 · English · DOAJ Scopus

    Utilising identical genetic aberrations but targeting different cells, Zhang and colleagues seek to uncover how the cell of origin influences high-grade serous ovarian cancer biology, metastasis and response to treatment.

  2. Journal Article

    Sub-acute Toxicity in Non-cancerous Tissue and Immune-Related Adverse Events of a Novel Combination Therapy for Cancer

    Kelly J. McKelvey; Amanda L. Hudson; Ramyashree Prasanna Kumar et al.

    Frontiers in Oncology, Vol. 9 · 2020 · English · DOAJ Scopus

    Brain, lung, and colon tissue experience deleterious immune-related adverse events when immune-oncological agents or radiation are administered. However, there is a paucity of information regarding whether the addition of radiation to immuno-oncological regimens exacerbates the tissue inflammatory…

  3. Journal Article

    Differential effects of radiation fractionation regimens on glioblastoma

    Kelly J. McKelvey; Amanda L. Hudson; Heather Donaghy et al.

    Radiation Oncology, Vol. 17 No. 1 · 2022 · English · DOAJ Scopus

    Abstract Background Radiotherapy (RT) is a mainstay of treatment for patients with glioblastoma (GB). Early clinical trials show that short course hypofractionation showed no survival benefit compared to conventional regimens with or without temozolomide chemotherapy (TMZ) but reduces the number of…

  4. Journal Article

    Glioblastoma Recurrence Correlates With Increased APE1 and Polarization Toward an Immuno-Suppressive Microenvironment

    Amanda L. Hudson; Nicole R. Parker; Peter Khong et al.

    Frontiers in Oncology, Vol. 8 · 2018 · English · DOAJ Scopus

    While treatment with surgery, radiotherapy and/or chemotherapy may prolong life for patients with glioblastoma, recurrence is inevitable. What is still being discovered is how much these treatments and recurrence of disease affect the molecular profiles of these tumors and how these tumors adapt to…

  5. Journal Article

    Overlooked potential of positrons in cancer therapy

    Takanori Hioki; Yaser H. Gholami; Kelly J. McKelvey et al.

    Scientific Reports, Vol. 11 No. 1 · 2021 · English · DOAJ Scopus

    Abstract Positron (β+) emitting radionuclides have been used for positron emission tomography (PET) imaging in diagnostic medicine since its development in the 1950s. Development of a fluorinated glucose analog, fluorodeoxyglucose, labelled with a β+ emitter fluorine-18 (18F-FDG), made it possible…

  6. Journal Article

    Glycolysis and Fatty Acid Oxidation Inhibition Improves Survival in Glioblastoma

    Kelly J. McKelvey; Erica B. Wilson; Susan Short et al.

    Frontiers in Oncology, Vol. 11 · 2021 · English · DOAJ Scopus

    Glioblastoma (GBM) is the most aggressive adult glioma with a median survival of 14 months. While standard treatments (safe maximal resection, radiation, and temozolomide chemotherapy) have increased the median survival in favorable O(6)-methylguanine-DNA methyltransferase (MGMT)-methylated GBM…

  7. Journal Article

    Comparison of radiobiological parameters for 90Y radionuclide therapy (RNT) and external beam radiotherapy (EBRT) in vitro

    Yaser H. Gholami; Kathy P. Willowson; Nicholas J. Forwood et al.

    EJNMMI Physics, Vol. 5 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background Dose rate variation is a critical factor affecting radionuclide therapy (RNT) efficacy. Relatively few studies to date have investigated the dose rate effect in RNT. Therefore, the aim of this study was to benchmark 90Y RNT (at different dose rates) against external beam…

  8. Journal Article Full text

    Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model

    Kelly J. McKelvey; Amanda L. Hudson; Ramyashree Prasanna Kumar et al.

    PLOS ONE, Vol. 15 No. 4 · 2020 · English · PLOS Scopus

    Glioblastoma, the most aggressive form of glioma, has a 5-year survival rate of 30% Ki67 and increased tissue vascularization (p

    Also available at: DOAJ

  9. Journal Article Full text

    BAMLET kills chemotherapy-resistant mesothelioma cells, holding oleic acid in an activated cytotoxic state

    Emma M. Rath; Yuen Yee Cheng; Mark Pinese et al.

    PLOS ONE, Vol. 13 No. 8 · 2018 · English · PLOS Scopus

    Malignant pleural mesothelioma is an aggressive cancer with poor prognosis. Here we have investigated in vitro efficacy of BAMLET and BLAGLET complexes (anti-cancer complexes consisting of oleic acid and bovine α-lactalbumin or β-lactoglobulin respectively) in killing mesothelioma cells, determined…

    Also available at: DOAJ

  10. Journal Article

    Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy

    Sumit Sahni; Christopher Nahm; Christoph Krisp et al.

    Frontiers in Oncology, Vol. 10 · 2020 · English · DOAJ Scopus

    Background: Neoadjuvant chemotherapy (NAC) has been of recent interest as an alternative to upfront surgery followed by adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC). However, a subset of patients does not respond to NAC and may have been better managed by upfront…